Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 16 Feb 2023
As more states repeal or restrict abortion laws, the number of patients, the number of workers needed, and the cost of heart disease will increase. How should hospitals and policy makers prepare?
Read Full NewsUse of immediate-release amantadine as an add-on to levodopa reduced peak-dose dyskinesia incidence in patients with early Parkinson disease, according to results from the phase 2 PREMANDYSK trial.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 16, 2026.
The therapy also received orphan drug designation from the FDA.
Phase 3 MODIFY Shows No Significant Renal Benefit With Lucerastat in Fabry Disease
HCPLive 5 Stories in Under 5: Week of 01/11
Topical Antioxidant Serum May Be Effective in Treating Atrophic Acne Scars
1.
Is Lenalidomide Resistance in Myeloma Reversible with JAK Inhibition?
2.
Advanced Solid Tumors May Benefit from Investigative Immunotherapy Combo.
3.
Pomalidomide Reduces Severe Epistaxis in Hereditary Bleeding Disease.
4.
A Win for AI in Cancer; 2025's Transformative Drugs; FDA Clarifies 'Underway' Trials
5.
FINAL USPSTF RECOMMENDATIONS ON ANXIETY, DEPRESSION, AND SUIICIDAL RISK.
1.
Oncology Partnerships: Driving Innovation Through Strategic Collaborations and Pharma Engagement USA
2.
CAR T-Cell Therapy: Revolutionizing Hematologic Malignancies
3.
Tazemetostat: A Promising New Treatment for Cancer
4.
Unveiling Tumor Immunity: Pan-Cancer Proteogenomics Characterization
5.
Understanding QSOFA: A Vital Tool for Recognizing Sepsis
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months
2.
Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V
4.
Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge